{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T07:59:00Z","timestamp":1719993540329},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T00:00:00Z","timestamp":1418256000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114646","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T14:07:19Z","timestamp":1418306839000},"page":"e114646","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy"],"prefix":"10.1371","volume":"9","author":[{"given":"Jian-wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-da","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can-ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-feng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen-hong","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-zhou","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"key":"ref1","first-page":"122","article-title":"Breast cancer. Clinical practice guidelines in oncology","volume":"7","author":"RW Carlson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1026564723698","article-title":"Long-term morbidity following axillary dissection in breast cancer patients\u2013clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors","volume":"64","author":"T Kuehn","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21535","article-title":"Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection","volume":"102","author":"T Ashikaga","year":"2010","journal-title":"J Surg Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"D Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/bjs.5894","article-title":"Neoadjuvant chemotherapy for operable breast cancer","volume":"94","author":"JS Mieog","year":"2007","journal-title":"Br J Surg"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-1164-9","article-title":"Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study","volume":"127","author":"F Fitzal","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"HD Bear","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/stem.150001","article-title":"HER-2\/neu signal transduction in human breast and ovarian cancer","volume":"15","author":"DM Reese","year":"1997","journal-title":"Stem Cells"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","article-title":"Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer","volume":"23","author":"AU Buzdar","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups","volume":"29","author":"M Untch","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdq041","article-title":"Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer","volume":"21","author":"XS Chen","year":"2010","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1634\/theoncologist.2012-0057","article-title":"Weekly paclitaxel\/carboplatin\/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule","volume":"18","author":"KD Yu","year":"2013","journal-title":"Oncologist"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"AC Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/jnci\/djj415","article-title":"Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays","volume":"98","author":"MM Regan","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.pai.0000213135.16783.bc","article-title":"Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy","volume":"15","author":"T Phillips","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Sobin L, Gospodarowicz M, Wittekind C (2009) UICC TNM classification of malignant tumours, 7th edn. New York: Wiley-Liss.","DOI":"10.1002\/9780471420194.tnmc29"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort","volume":"375","author":"L Gianni","year":"2010","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"J Baselga","year":"2012","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"L Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","volume":"14","author":"A Robidoux","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","article-title":"Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial","volume":"8","author":"DN Krag","year":"2007","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-006-9330-9","article-title":"Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients","volume":"102","author":"S Lee","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1245\/s10434-007-9403-y","article-title":"Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation","volume":"14","author":"EA Newman","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/cncr.22540","article-title":"Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases","volume":"109","author":"J Shen","year":"2007","journal-title":"Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","article-title":"The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer","volume":"19","author":"R Alvarado","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.2008.18.3228","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study","volume":"27","author":"JM Classe","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"T Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"JC Boughey","year":"2013","journal-title":"JAMA"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1200\/JCO.2005.08.001","article-title":"American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer","volume":"23","author":"GH Lyman","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1200\/JCO.20.5.1304","article-title":"Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes","volume":"20","author":"R Rouzier","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1200\/JCO.2008.21.7554","article-title":"Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer","volume":"28","author":"ME Straver","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","article-title":"Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial","volume":"14","author":"V Galimberti","year":"2013","journal-title":"Lancet Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"AE Giuliano","year":"2011","journal-title":"JAMA"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T06:52:22Z","timestamp":1566111142000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114646"}},"subtitle":[],"editor":[{"given":"Mohammad O.","family":"Hoque","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,11]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114646","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,11]]}}}